MedTrace Logo

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-03-19

Study results available
· View outcomes & findings →

Summary

The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Conditions

Interventions

DRUG

Galantamine

16 mg po prior to the infusion of intralipid

DRUG

Placebo Oral Capsule

Placebo oral capsule prior to the infusion of intralipid/heparin

DRUG

Intralipid

Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine

DRUG

Heparin

heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine

Sponsors & Collaborators

  • Doris Duke Charitable Foundation

    collaborator OTHER

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Cyndya Shibao, MD · Vanderbilt University Medical Center, Clinical Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-10-05
Completion
2017-10-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02365285 on ClinicalTrials.gov